Abstract
Background. Technical limitations in the sensitivity of commercial genotyping methods may prevent clinicians from determining whether drug-resistant human immunodeficiency virus type 1 (HIV-1) is present in patients with low-level viremia. We performed ultrasensitive HIV-1 genotyping for patients with persistent plasma virus loads of 50-400 copies/mL to better define the prevalence of drug resistance and the most common resistance mutations during persistently detectable low-level viremia. Methods. Genotyping of HIV-1 was performed with an ultrasensitive clonal genotyping method. Results. We studied 21 patients who had persistent, detectable, low-level viremia for a median of 11 months. Nine (43%) of 21 patients had HIV-1 isolates with significant resistance mutations. The most common mutations were M184V, K65R, and M41L/T215Y. Conclusions. The finding that clinically significant resistance mutations were present in some but not all patients with persistent viremia (range, 50-400 copies/mL) highlights the need to improve the sensitivity of current clinical assays for detection of drug resistance.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1030-1037 |
| Number of pages | 8 |
| Journal | Clinical Infectious Diseases |
| Volume | 39 |
| Issue number | 7 |
| DOIs | |
| State | Published - Oct 1 2004 |
Fingerprint
ASJC Scopus subject areas
- Immunology
Cite this
Genotypic resistance in HIV-1-infected patients with persistently detectable low-level viremia while receiving highly active antiretroviral therapy. / Nettles, Richard E.; Kieffer, Tara L.; Simmons, Rachel P.; Cofrancesco, Joseph; Moore, Richard D; Gallant, Joel E.; Persaud, Deborah; Siliciano, Robert F.
In: Clinical Infectious Diseases, Vol. 39, No. 7, 01.10.2004, p. 1030-1037.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Genotypic resistance in HIV-1-infected patients with persistently detectable low-level viremia while receiving highly active antiretroviral therapy
AU - Nettles, Richard E.
AU - Kieffer, Tara L.
AU - Simmons, Rachel P.
AU - Cofrancesco, Joseph
AU - Moore, Richard D
AU - Gallant, Joel E.
AU - Persaud, Deborah
AU - Siliciano, Robert F
PY - 2004/10/1
Y1 - 2004/10/1
N2 - Background. Technical limitations in the sensitivity of commercial genotyping methods may prevent clinicians from determining whether drug-resistant human immunodeficiency virus type 1 (HIV-1) is present in patients with low-level viremia. We performed ultrasensitive HIV-1 genotyping for patients with persistent plasma virus loads of 50-400 copies/mL to better define the prevalence of drug resistance and the most common resistance mutations during persistently detectable low-level viremia. Methods. Genotyping of HIV-1 was performed with an ultrasensitive clonal genotyping method. Results. We studied 21 patients who had persistent, detectable, low-level viremia for a median of 11 months. Nine (43%) of 21 patients had HIV-1 isolates with significant resistance mutations. The most common mutations were M184V, K65R, and M41L/T215Y. Conclusions. The finding that clinically significant resistance mutations were present in some but not all patients with persistent viremia (range, 50-400 copies/mL) highlights the need to improve the sensitivity of current clinical assays for detection of drug resistance.
AB - Background. Technical limitations in the sensitivity of commercial genotyping methods may prevent clinicians from determining whether drug-resistant human immunodeficiency virus type 1 (HIV-1) is present in patients with low-level viremia. We performed ultrasensitive HIV-1 genotyping for patients with persistent plasma virus loads of 50-400 copies/mL to better define the prevalence of drug resistance and the most common resistance mutations during persistently detectable low-level viremia. Methods. Genotyping of HIV-1 was performed with an ultrasensitive clonal genotyping method. Results. We studied 21 patients who had persistent, detectable, low-level viremia for a median of 11 months. Nine (43%) of 21 patients had HIV-1 isolates with significant resistance mutations. The most common mutations were M184V, K65R, and M41L/T215Y. Conclusions. The finding that clinically significant resistance mutations were present in some but not all patients with persistent viremia (range, 50-400 copies/mL) highlights the need to improve the sensitivity of current clinical assays for detection of drug resistance.
UR - http://www.scopus.com/inward/record.url?scp=4744362201&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=4744362201&partnerID=8YFLogxK
U2 - 10.1086/423388
DO - 10.1086/423388
M3 - Article
C2 - 15472857
AN - SCOPUS:4744362201
VL - 39
SP - 1030
EP - 1037
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
SN - 1058-4838
IS - 7
ER -